Treatment - Page 29 of 471 Posts on Medivizor

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Posted by Medivizor on Jan 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR (epidermal growth factor receptor) plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with 5-fluorouracil...

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by Medivizor on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Posted by Medivizor on Dec 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia. Some background...

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Posted by Medivizor on Dec 31, 2021 in Parkinson's Disease | 0 comments

In a nutshell In this work, the authors studied whether VY-AADC01 (NBIb-1817) gene therapy was safe and effective in patients with moderately advanced Parkinson's disease (PD) patients with motor fluctuations. The authors showed that this treatment caused an improvement in motor function, quality of life, and a decrease in the level of...

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by Medivizor on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva). This study concluded that this treatment leads to an effective MRD reduction and has...

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Posted by Medivizor on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML). This study concluded that this treatment was safe and effective in the long-term in these...

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Posted by Medivizor on Dec 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients. Some background Colorectal...

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by Medivizor on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Posted by Medivizor on Dec 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Posted by Medivizor on Dec 19, 2021 in Hypertension | 0 comments

In a nutshell This study investigated whether a single blood pressure (BP) pill containing 4 drugs (quadpill) at quarter doses is more effective than the standard dose of a single drug as initial treatment in patients with hypertension. The data showed that a quadpill was safe and more effective in getting BP under control than the standard...

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Posted by Medivizor on Dec 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-based therapy for patients with multiple myeloma (MM) in a real-world setting. The data showed that daratumumab-based therapy in a real-world setting was not as effective as in clinical trials. Some background Multiple myeloma (MM) is a type of cancer that comes from...

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Posted by Medivizor on Dec 19, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...

Treatment Posts on Medivizor

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email